Industry News — Clinical Updates
Regeneron and Bayer to Develop PDGFR-Beta Antibody
Regeneron Pharmaceuticals, Inc. (Tarrytown, NY) and Bayer HealthCare (Leverkusen, Germany) announced that they will jointly develop a platelet-derived growth factor receptor beta (PDGFR-beta) antibody as a potential combination therapy with aflibercept for treating wet AMD.
Preclinical data suggest that combining the PDGFR-beta blockade with the VEGF blockade of aflibercept can provide advantages over inhibiting VEGF alone in treating wet AMD. First in-human clinical studies are planned to begin in early 2014.
Under terms of the agreement, Bayer HealthCare will have exclusive commercialization rights to the combination product outside the United States, where it will share profits from non-United States sales equally with Regeneron. Regeneron will have exclusive commercialization rights within the United States and retain 100% of the profits.
Updated: January 13, 2014